Shaanxi Micot Pharmaceutical Technology Co., Ltd.

This study tests a new drug called MT200605 in 360 people who have had an acute ischemic stroke within the past 24 hours. The drug aims to protect brain cells and reduce damage from the stroke. Participants will receive either a high, medium, or low dose of the drug or a placebo,…

This Phase 3 trial tests a new drug called MT1013 against an existing drug, cinacalcet, in 424 adults on dialysis who have secondary hyperparathyroidism (overactive parathyroid glands). The study aims to see if MT1013 better controls parathyroid hormone levels and improves bone h…

This early-stage study looks at how the experimental drug MT1013 moves through and leaves the body of people on hemodialysis who have secondary hyperparathyroidism. Six participants will receive a single dose, and researchers will measure radioactivity in blood, urine, and stool …